Professional Documents
Culture Documents
By Dr Upul Udayaraj
Hepatitis may be acute or chronic
Depending on whether it lasts for less than or more than six months
Outcome
• Acute hepatitis
Can sometimes resolve on its own
Progress to chronic hepatitis
Rarely result in acute liver failure
• Chronic hepatitis
May progress to Cirrhosis
Liver failure or hepatic insufficiency
Liver cancer
Causes
• Infectious
• Metabolic
• Ischemic
• Autoimmune
• Genetic
Viral hepatitis
Parasitic hepatitis
Bacterial hepatitis
• Other
• Cytomegalovirus (CMV),
• Yellow fever
Globally, symptomatic HAV infections are believed to occur in around 1.4
million people a year
• Less commonly, having sex with someone who has the infection (particularly a risk
for homosexual men) or injecting drugs using contaminated equipment
Someone with hepatitis A is most infectious from around two weeks before their
symptoms appear until about a week after the symptoms first develop
Clinical picture
Dark urine
Pale stools
Itchy skin
Spread
Through exposure to infected blood or body fluids
Vertical transmission from mother to child
Hepatocellular carcinoma
Glomerulonephritis
Polyarteritis nodosa
Cryoglobulinaemia
Surface antigen (HBsAg) is the first marker to appear and causes the production of anti-HBs
If HBsAg is present for > 6 months then this implies chronic disease (i.e. Infective)
IgM anti-HBc appears during acute or recent hepatitis B infection and is present for about 6 months
HbeAg results from breakdown of core antigen from infected liver cells as is therefore a marker of infectivity
Previous immunization:
Treatment options
• Antivirals
• Tenofovir
• Entecavir
• Interferon injections
HBsAg positive source: if the person exposed is a known responder to HBV
vaccine then a booster dose should be given. If they are in the process of being
vaccinated or are a non-responder they need to have hepatitis B immune
globulin (HBIG) and the vaccine
Unknown source: for known responders the green book advises considering a
booster dose of HBV vaccine. For known non-responders HBIG + vaccine should
be given whilst those in the process of being vaccinated should have an
accelerated course of HBV vaccine
All pregnant women are offered screening for hepatitis B
Babies born to mothers who are chronically infected with hepatitis B or to
mothers who've had acute hepatitis B during pregnancy should receive a
complete course of vaccination + hepatitis B immunoglobulin
Studies are currently evaluating the role of oral antiviral treatment (e.g.
Lamivudine) in the latter part of pregnancy
There is little evidence to suggest caesarean section reduces vertical
transmission rates
Hepatitis B cannot be transmitted via breastfeeding (in contrast to HIV)
Transmission
The risk of transmission during a needle stick injury is about 2%
Chronic infection (80-85%) - only 15-20% of patients will clear the virus after
an acute infection and hence the majority will develop chronic hepatitis C
Hepatocellular cancer
Cryoglobulinemia
• People who have lived or had medical treatment in an area where hepatitis C is common – high-
risk areas include north Africa, the Middle East and central and east Asia
• People who have received a tattoo or piercing where equipment may not have been properly
sterilized
Hepatitis C medications
Until relatively recently, treatment for chronic hepatitis C usually involved taking two main
drugs:
o Pegylated interferon
o Ribavirin
These medications were frequently just taken together
Superinfection:
- A hepatitis B surface antigen positive patient subsequently
develops a hepatitis D infection
It is a RNA hepevirus